Discovery and development of varenicline for smoking cessation

References

• Samet, JM, Yoon, SY (Eds). Gender, women, and the tobacco epidemic. World Health Organization. 2010. Manilla, Phillipines.
   Google Scholar
• World Health Organization. Tobacco fact sheet. 2015 [cited 2017 Oct 11]. Available from: http://www.who.int/mediacentre/factsheets/fs339/en/
   Google Scholar
• Center for Disease Control and Prevention. Tobacco fact sheet. 2017 [cited 2017 Oct 11]. Available from: https://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/index.htm
   Google Scholar
• Center for Disease Control and Prevention. Chronic disease overview. 2017 [cited 2017 Nov 2]. Available from: https://www.cdc.gov/chronicdisease/overview/index.htm
   Google Scholar
• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
   Google Scholar
• Messer K, Trinidad DR, Al-Delaimy WK, et al. Smoking cessation rates in the United States: a comparison of young adult and older smokers. Am J Public Health. 2008 Feb;98(2):317–322.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. The health consequences of smoking—50 years of progress: a report of the surgeon general. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2014. Washington D.C., USA.
   Google Scholar
• Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol. 2009;49:57–71.
   PubMed Web of Science ®Google Scholar
• Jones S, Sudweeks S, Yakel JL. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci. 1999 Dec;22(12):555–561.
   PubMed Web of Science ®Google Scholar
• Xi ZX. Preclinical pharmacology. Efficacy and safety of varenicline in smoking cessation and clinical utility in high risk patients. Drug Healthc Patient Saf. 2010;2:39–48. [cited 2010 Apr 01].
   PubMedGoogle Scholar
• Le Novere N, Corringer PJ, Changeux JP. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J Neurobiol. 2002 Dec;53(4):447–456.
   PubMedGoogle Scholar
• Garduno J, Galindo-Charles L, Jimenez-Rodriguez J, et al. Presynaptic alpha4beta2 nicotinic acetylcholine receptors increase glutamate release and serotonin neuron excitability in the dorsal raphe nucleus. J Neurosci. 2012 Oct 24;32(43):15148–15157.
   PubMed Web of Science ®Google Scholar
• Miyazawa A, Fujiyoshi Y, Unwin N. Structure and gating mechanism of the acetylcholine receptor pore. Nature. 2003 Jun 26;423(6943):949–955.
   PubMed Web of Science ®Google Scholar
• Clarke PB, Pert A. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. 1985 Dec 02;348(2):355–358.
   PubMed Web of Science ®Google Scholar
• Ikemoto S. Brain reward circuitry beyond the mesolimbic dopamine system: a neurobiological theory. Neurosci Biobehav Rev. 2010 Nov;35(2):129–150.
   PubMed Web of Science ®Google Scholar
• Pontieri FE, Tanda G, Orzi F, et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 1996 Jul 18;382(6588):255–257.
   PubMed Web of Science ®Google Scholar
• Zhang T, Zhang L, Liang Y, et al. Dopamine signaling differences in the nucleus accumbens and dorsal striatum exploited by nicotine. J Neurosci. 2009 Apr 01;29(13):4035–4043.
   PubMed Web of Science ®Google Scholar
• Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006 Aug;63(8):907–915.
   PubMed Web of Science ®Google Scholar
• Watkins SS, Epping-Jordan MP, Koob GF, et al. Blockade of nicotine self-administration with nicotinic antagonists in rats. Pharmacol Biochem Behav. 1999 Apr;62(4):743–751.
   PubMed Web of Science ®Google Scholar
• Pons S, Fattore L, Cossu G, et al. Crucial role of alpha4 and alpha6 nicotinic acetylcholine receptor subunits from ventral tegmental area in systemic nicotine self-administration. J Neurosci. 2008 Nov 19;28(47):12318–12327.
   PubMed Web of Science ®Google Scholar
• Liu L, Zhao-Shea R, McIntosh JM, et al. Nicotine persistently activates ventral tegmental area dopaminergic neurons via nicotinic acetylcholine receptors containing alpha4 and alpha6 subunits. Mol Pharmacol. 2012 Apr;81(4):541–548.
   PubMed Web of Science ®Google Scholar
• Tapper AR, McKinney SL, Nashmi R, et al. Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization. Science. 2004 Nov 05;306(5698):1029–1032.
   PubMed Web of Science ®Google Scholar
• Carroll FI, Blough BE, Mascarella SW, et al. Bupropion and bupropion analogs as treatments for CNS disorders. Adv Pharmacol. 2014;69:177–216.
   PubMedGoogle Scholar
• Damaj MI, Kao W, Martin BR. Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J Pharmacol Exp Ther. 2003 Nov;307(2):526–534.
   PubMed Web of Science ®Google Scholar
• Hughes JR, Higgins ST, Bickel WK. Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction. 1994 Nov;89(11):1461–1470.
   PubMed Web of Science ®Google Scholar
• Jackson A. Partial agonist. In: Stolerman IP, editor. Encyclopedia of psychopharmacology. 2010. Springer, Berlin, Heidelberg
   Google Scholar
• Jeong SH, Newcombe D, Sheridan J, et al. Pharmacokinetics of cytisine, an alpha4 beta2 nicotinic receptor partial agonist, in healthy smokers following a single dose. Drug Test Anal. 2015 Jun;7(6):475–482.
   PubMed Web of Science ®Google Scholar
• Radchenko EV, Dravolina OA, Bespalov AY. Agonist and antagonist effects of cytisine in vivo. Neuropharmacology. 2015 Aug;95:206–214.
   PubMed Web of Science ®Google Scholar
• Prochaska JJ, Das S, Benowitz NL. Cytisine, the world’s oldest smoking cessation aid. BMJ. 2013 Aug;23(347):f5198.
   Google Scholar
• Dale HH, Laidlaw PP. The physiological action of cytisine, the active alkaloid of laburnum (cytisus-laburnum). J Pharmacol Exp Ther. 1912;3(3):22.
   Google Scholar
• West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med. 2011 Sep 29;365(13):1193–1200.
   PubMed Web of Science ®Google Scholar
• Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax. 2013 Nov;68(11):1037–1042.
   PubMed Web of Science ®Google Scholar
• Reavill C, Walther B, Stolerman IP, et al. Behavioural and pharmacokinetic studies on nicotine, cytisine and lobeline. Neuropharmacology. 1990 Jul;29(7):619–624.
   PubMed Web of Science ®Google Scholar
• Walker N, Howe C, Glover M, et al. Cytisine versus nicotine for smoking cessation. N Engl J Med. 2014 Dec 18;371(25):2353–2362.
   PubMed Web of Science ®Google Scholar
• Walker N, Bullen C, Barnes J, et al. Getting cytisine licensed for use world-wide: a call to action. Addiction. 2016 Nov;111(11):1895–1898.
   PubMed Web of Science ®Google Scholar
• Drug Patent Watch. Chantix drug profile. 2017 [cited 2017 Nov 22]; Available from: https://www.drugpatentwatch.com/p/tradename/CHANTIX.
   Google Scholar
• Pfizer Labs P. Chantix (varenicline) tablets medication guide. 2009. Pfizer Inc., New York, New York.
   Google Scholar
• Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005 May 19;48(10):3474–3477.
   PubMed Web of Science ®Google Scholar
• Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007 Mar;52(3):985–994.
   PubMed Web of Science ®Google Scholar
• Rollema H, Coe JW, Chambers LK, et al. Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation. Trends Pharmacol Sci. 2007 Jul;28(7):316–325.
   PubMed Web of Science ®Google Scholar
• Bordia T, Hrachova M, Chin M, et al. Varenicline is a potent partial agonist at alpha6beta2* nicotinic acetylcholine receptors in rat and monkey striatum. J Pharmacol Exp Ther. 2012 Aug;342(2):327–334.
   PubMed Web of Science ®Google Scholar
• Biala G, Staniak N, Budzynska B. Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. Naunyn Schmiedebergs Arch Pharmacol. 2010 Apr;381(4):361–370.
   PubMed Web of Science ®Google Scholar
• Goutier W, Kloeze MB, McCreary AC. The effect of varenicline on the development and expression of nicotine-induced behavioral sensitization and cross-sensitization in rats. Addict Biol. 2015 Mar;20(2):248–258.
   PubMed Web of Science ®Google Scholar
• Le Foll B, Chakraborty-Chatterjee M, Lev-Ran S, et al. Varenicline decreases nicotine self-administration and cue-induced reinstatement of nicotine-seeking behaviour in rats when a long pretreatment time is used. Int J Neuropsychopharmacol. 2012 Oct;15(9):1265–1274.
   PubMed Web of Science ®Google Scholar
• O’Connor EC, Parker D, Rollema H, et al. The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berl). 2010 Feb;208(3):365–376.
   PubMed Web of Science ®Google Scholar
• Spiller K, Xi ZX, Li X, et al. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats. Neuropharmacology. 2009 Jul;57(1):60–66.
   PubMed Web of Science ®Google Scholar
• Igari M, Alexander JC, Ji Y, et al. Varenicline and cytisine diminish the dysphoric-like state associated with spontaneous nicotine withdrawal in rats. Neuropsychopharmacology. 2014 Jan;39(2):455–465.
   PubMed Web of Science ®Google Scholar
• Funk D, Lo S, Coen K, et al. Effects of varenicline on operant self-administration of alcohol and/or nicotine in a rat model of co-abuse. Behav Brain Res. 2016 Jan 1;296:157–162.
   PubMed Web of Science ®Google Scholar
• Panlilio LV, Hogarth L, Shoaib M. Concurrent access to nicotine and sucrose in rats. Psychopharmacology (Berl). 2015 Apr;232(8):1451–1460.
   PubMed Web of Science ®Google Scholar
• Schassburger RL, Levin ME, Weaver MT, et al. Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline. Psychopharmacology (Berl). 2015 Mar;232(5):975–983.
   PubMed Web of Science ®Google Scholar
• Costello MR, Reynaga DD, Mojica CY, et al. Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats. Neuropsychopharmacology. 2014 Jul;39(8):1843–1851.
   PubMed Web of Science ®Google Scholar
• Mello NK, Fivel PA, Kohut SJ, et al. Effects of chronic varenicline treatment on nicotine, cocaine, and concurrent nicotine+cocaine self-administration. Neuropsychopharmacology. 2014 Apr;39(5):1222–1231.
   PubMed Web of Science ®Google Scholar
• Levin ME, Weaver MT, Palmatier MI, et al. Varenicline dose dependently enhances responding for nonpharmacological reinforcers and attenuates the reinforcement-enhancing effects of nicotine. Nicotine Tob Res. 2012 Mar;14(3):299–305.
   PubMed Web of Science ®Google Scholar
• de Moura FB, McMahon LR. The contribution of alpha4beta2 and non-alpha4beta2 nicotinic acetylcholine receptors to the discriminative stimulus effects of nicotine and varenicline in mice. Psychopharmacology (Berl). 2017 Mar;234(5):781–792.
   PubMed Web of Science ®Google Scholar
• Paterson NE, Min W, Hackett A, et al. The high-affinity nAChR partial agonists varenicline and sazetidine-A exhibit reinforcing properties in rats. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Dec 01;34(8):1455–1464.
   PubMed Web of Science ®Google Scholar
• Biala G, Staniak N. Varenicline and mecamylamine attenuate locomotor sensitization and cross-sensitization induced by nicotine and morphine in mice. Pharmacol Biochem Behav. 2010 Aug;96(2):141–147.
   PubMed Web of Science ®Google Scholar
• Turner JR, Castellano LM, Blendy JA. Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline. Nicotine Tob Res. 2011 Jan;13(1):41–46.
   PubMed Web of Science ®Google Scholar
• Marks MJ, O’Neill HC, Wynalda-Camozzi KM, et al. Chronic treatment with varenicline changes expression of four nAChR binding sites in mice. Neuropharmacology. 2015;99:142–155.
   PubMed Web of Science ®Google Scholar
• Obach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006 Jan;34(1):121–130.
   PubMed Web of Science ®Google Scholar
• Garrison GD, Dugan SE. Varenicline: a first-line treatment option for smoking cessation. Clin Ther. 2009 Mar;31(3):463–491.
   PubMed Web of Science ®Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 05;296(1):56–63.
   PubMed Web of Science ®Google Scholar
• Ramon JM, Morchon S, Baena A, et al. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. BMC Med. 2014 Oct;8(12):172.
   Google Scholar
• Moore TJ Strong safety signal seen for new varenicline risks. 2008 [cited 2017 Nov 24]; Available from: http://www.ismp.org/docs/vareniclinestudy.asp
   Google Scholar
• Oncken C, Gonzales D, Nides M, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006 Aug 1428;166(15):1571–1577.
   PubMed Web of Science ®Google Scholar
• Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 05;296(1):47–55.
   PubMed Web of Science ®Google Scholar
• Niaura R, Hays JT, Jorenby DE, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. Curr Med Res Opin. 2008 Jul;24(7):1931–1941.
   PubMed Web of Science ®Google Scholar
• Waknine Y. FDA rovals: chantix. Medscape; 2006 [cited 2017 Nov 24]. Available from: https://www.medscape.org/viewarticle/532569
   Google Scholar
• Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006 Jul 5;296(1):64–71.
   PubMed Web of Science ®Google Scholar
• Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax. 2008 Aug;63(8):717–724.
   PubMed Web of Science ®Google Scholar
• Nides M, Glover ED, Reus VI, et al. Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav. 2008 Nov-Dec;32(6):664–675.
   PubMed Web of Science ®Google Scholar
• Benli AR, Erturhan S, Oruc MA, et al. A comparison of the efficacy of varenicline and bupropion and an evaluation of the effect of the medications in the context of the smoking cessation programme. Tob Induc Dis. 2017;15:10.
   PubMed Web of Science ®Google Scholar
• Cinciripini PM, Robinson JD, Karam-Hage M, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. JAMA Psychiatry. 2013 May;70(5):522–533.
   PubMed Web of Science ®Google Scholar
• Ebbert JO, Croghan IT, Hurt RT, et al. Varenicline for smoking cessation in light smokers. Nicotine Tob Res. 2016 Oct;18(10):2031–2035.
   PubMed Web of Science ®Google Scholar
• West R, Baker CL, Cappelleri JC, et al. Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt. Psychopharmacology (Berl). 2008 Apr;197(3):371–377.
   PubMed Web of Science ®Google Scholar
• Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2008 Jul;16(3):CD006103.
   Google Scholar
• Mills EJ, Wu P, Spurden D, et al. Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduct J. 2009 Sep;18(6):25.
   Google Scholar
• Cahill K, Lindson-Hawley N, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016 May;09(5):CD006103.
   Google Scholar
• Loughead J, Ray R, Wileyto EP, et al. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. Biol Psychiatry. 2010 Apr 15;67(8):715–721.
   PubMed Web of Science ®Google Scholar
• Hartwell KJ, Lematty T, McRae-Clark AL, et al. Resisting the urge to smoke and craving during a smoking quit attempt on varenicline: results from a pilot fMRI study. Am J Drug Alcohol Abuse. 2013 Mar;39(2):92–98.
   PubMed Web of Science ®Google Scholar
• Lesage E, Aronson SE, Sutherland MT, et al. Neural signatures of cognitive flexibility and reward sensitivity following nicotinic receptor stimulation in dependent smokers: a randomized trial. JAMA Psychiatry. 2017 Jun 01;74(6):632–640.
   PubMed Web of Science ®Google Scholar
• Franklin T, Wang Z, Suh JJ, et al. Effects of varenicline on smoking cue-triggered neural and craving responses. Arch Gen Psychiatry. 2011 May;68(5):516–526.
   PubMed Web of Science ®Google Scholar
• Cinciripini PM, Green CE, Robinson JD, et al. Benefits of varenicline vs. Bupropion for smoking cessation: a Bayesian analysis of the interaction of reward sensitivity and treatment. Psychopharmacology (Berl). 2017 Jun;234(11):1769–1779.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Varenicline (marketed as chantix) information. 2016 [cited 2017 Nov 24]; Available from: https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106540.htm.
   Google Scholar
• Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016 Jun 18;387(10037):2507–2520.
   PubMed Web of Science ®Google Scholar
• Littlewood RA, Claus ED, Wilcox CE, et al. Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo. Psychopharmacology (Berl). 2017 Dec;234(23–24):3417–3429.
   PubMed Web of Science ®Google Scholar
• Gomez-Mancilla B, Marrer E, Kehren J, et al. Central nervous system drug development: an integrative biomarker approach toward individualized medicine. NeuroRx. 2005 Oct;2(4):683–695.
   PubMedGoogle Scholar
• Federal Aviation Administration. Anti-smoking medicine chantix banned. 2008 [cited 2017 Nov 24]; Available from: https://www.faa.gov/news/updates/?newsId=56363.
   Google Scholar
• Selcuk EB, Sungu M, Parlakpinar H, et al. Evaluation of the cardiovascular effects of varenicline in rats. Drug Des Devel Ther. 2015;9:5705–5717.
   PubMed Web of Science ®Google Scholar
• Rigotti NA, Pipe AL, Benowitz NL, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. . Circulation. 2010 Jan 18;121(2):221–229.
   PubMed Web of Science ®Google Scholar
• Benowitz NL, West R, Pipe A, et al. PA1-3: cardiovascular safety of varenicline, bupropion, and nicotine patch: a double-blind, randomized, placebo controlled clinical trial. Florence, Italy: Society for Research on Nicotine and Tobacco; 2017.
   Google Scholar
• U.S. Department of Health and Human Services. E-cigarette use among youth and young adults: a report of the Surgeon General. 2016.
   Google Scholar
• American Lung Association. E-cigarettes and lung health. 2016 [cited 2018 Mar 7]; Available from: http://www.lung.org/stop-smoking/smoking-facts/e-cigarettes-and-lung-health.html
   Google Scholar
• Rehan HS, Maini J, Hungin AP. Vaping versus smoking: a quest for efficacy and safety of E-cigarette. Curr Drug Saf. 2018 Epub Ahead of Print. Available online Feb 26.
   PubMedGoogle Scholar
• Jordan CJ, Andersen SL. Sensitive periods of substance abuse: early risk for the transition to dependence. Dev Cogn Neurosci. 2017 Jun;25:29–44.
   PubMed Web of Science ®Google Scholar
• Substance Abuse and Mental Health Services Administration. 2014 National Survey on Drug Use and Health: detailed tables. Rockville, MD: Center for Behavioral Health Statistics and Quality; 2015.
   Google Scholar
• Xi ZX, Spiller K, Gardner EL. Mechanism-based medication development for the treatment of nicotine dependence. Acta Pharmacol Sin. 2009 Jun;30(6):723–739.
   PubMed Web of Science ®Google Scholar
• Picciotto MR, Zoli M, Rimondini R, et al. Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine. Nature. 1998 Jan 08;391(6663):173–177.
   PubMed Web of Science ®Google Scholar
• Cross AJ, Anthenelli R, Metabotropic glutamate receptors 2 and 3 as targets for treating nicotine addiction. Biol psychiatry. 2017, Epub ahead of print. Available online Nov 21.
   PubMed Web of Science ®Google Scholar
• Justinova Z, Le Foll B, Redhi GH, et al. Differential effects of the metabotropic glutamate 2/3 receptor agonist LY379268 on nicotine versus cocaine self-administration and relapse in squirrel monkeys. Psychopharmacology (Berl). 2016 May;233(10):1791–1800.
   PubMed Web of Science ®Google Scholar
• Liechti ME, Lhuillier L, Kaupmann K, et al. Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci. 2007 Aug 22;27(34):9077–9085.
   PubMed Web of Science ®Google Scholar
• D’Souza MS, Liechti ME, Ramirez-Nino AM, et al. The metabotropic glutamate 2/3 receptor agonist LY379268 blocked nicotine-induced increases in nucleus accumbens shell dopamine only in the presence of a nicotine-associated context in rats. Neuropsychopharmacology. 2011 Sep;36(10):2111–2124.
   PubMed Web of Science ®Google Scholar
• Li X, D’Souza MS, Nino AM, et al. Attenuation of nicotine-taking and nicotine-seeking behavior by the mGlu2 receptor positive allosteric modulators AZD8418 and AZD8529 in rats. Psychopharmacology (Berl). 2016 May;233(10):1801–1814.
   PubMed Web of Science ®Google Scholar
• Justinova Z, Panlilio LV, Secci ME, et al. The novel metabotropic glutamate receptor 2 positive allosteric modulator, AZD8529, decreases nicotine self-administration and relapse in squirrel monkeys. Biol Psychiatry. 2015 Oct 1;78(7):452–462.
   PubMed Web of Science ®Google Scholar
• Kenny PJ, Paterson NE, Boutrel B, et al. Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats. Ann N Y Acad Sci. 2003;1003:415–418.
   PubMed Web of Science ®Google Scholar
• Paterson NE, Semenova S, Gasparini F, et al. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl). 2003 May;167(3):257–264.
   PubMed Web of Science ®Google Scholar
• Tessari M, Pilla M, Andreoli M, et al. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur J Pharmacol. 2004 Sep 19;499(1–2):121–133.
   PubMed Web of Science ®Google Scholar
• Bespalov AY, Dravolina OA, Sukhanov I, et al. Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology. 2005;49(Suppl 1):167–178.
   PubMedGoogle Scholar
• Stoker AK, Olivier B, Markou A. Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal. Psychopharmacology (Berl). 2012 May;221(2):317–327.
   PubMed Web of Science ®Google Scholar
• Wegener G, Rujescu D. The current development of CNS drug research. Int J Neuropsychopharmacol. 2013 Aug;16(7):1687–1693.
   PubMed Web of Science ®Google Scholar
• Coe JW, Rollema H, O’Neill BT. Case history: ChantixTM/ChampixTM (varenicline tartrate), a nicotinic acetylcholine receptor partial agonist as a smoking cessation aid. Annual Rep Med Chem. 2009;44:71–101.
   Web of Science ®Google Scholar
• Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, Reeves KR. Smoking cessation with varenicline, a selective α4β2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med. 2006;166(15):1561–1568.
   PubMedGoogle Scholar